BioPharma Credit PLC

BPCP

GB00BDGKMY29

Closed End Funds

Market Closed - London S.E. Other stock markets 11:35:25 2024-04-26 am EDT			5-day change	1st Jan Change
0.878 ^USD	+0.23%		+0.23%	+4.52%

Apr. 24	BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals	MT
Apr. 24	BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals	AN

Biopharma Credit plc Declares Interim Dividend in Respect of the Financial Period Ending 31 March 2024, Payable on 30 April 2024

March 21, 2024 at 12:05 pm EDT

BioPharma Credit PLC declared an interim dividend in respect of the financial period ending 31 March 2024 of $0.0175 per ordinary share, payable on 30 April 2024 to ordinary shareholders on the register as at 2 April 2024. The ex-dividend date will be 28 March 2024. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution.

Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.

Latest news about BioPharma Credit PLC

BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals	Apr. 24	MT
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals	Apr. 24	AN
BioPharma Credit PLC Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
BioPharma Credit net asset value ticks up but total payout lower	Mar. 27	AN
BioPharma Credit Board, Investment Manager Propose Changes to Discount Control Mechanism	Mar. 27	MT
BioPharma Credit Logs Lower FY23 Net Income Return on Ordinary Activities	Mar. 27	MT
Tranche Update on BioPharma Credit PLC's Equity Buyback Plan announced on May 31, 2023.	Mar. 27	CI
Biopharma Credit plc Declares Interim Dividend in Respect of the Financial Period Ending 31 March 2024, Payable on 30 April 2024	Mar. 21	CI
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	Feb. 13	AN
Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen	Feb. 13	MT
BioPharma Credit PLC Declares Interim Special Dividend in Respect of the Financial Period Ending 31 December 2023, Payable on 15 March 2024	Feb. 08	CI
BioPharma Credit PLC Declares Ordinary Interim Dividend in Respect of the Financial Period Ending 31 December 2023, Payable on 15 March 2024	Feb. 08	CI
Jefferies Downgrades BioPharma Credit to Hold from Buy	Feb. 07	MT
Jefferies cuts BioPharma Credit to 'hold'	Feb. 07	AN
Barratt takes over Redrow in GBP2.5 billion deal	Feb. 07	AN
BioPharma Credit to receive partial prepayment of loan	Feb. 06	AN
BioPharma Credit to fund LumiraDx ahead of acquisition by Roche	Jan. 02	AN
BioPharma Credit notes loan agreement amendment by LumiraDx	Dec. 12	AN
BioPharma Credit notes AbbVie takeover of investee ImmunoGen	Dec. 01	AN
Biopharma Credit plc Declares Special Dividend in Respect of the Financial Period Ended 30 September 2023, Payable on 5 January 2024	Nov. 29	CI
BioPharma Credit PLC Declares Interim Dividend in Respect of the Financial Period Ended 30 September 2023, Payable on 5 January 2024	Nov. 29	CI
BioPharma Credit says liquidity covenant in loan deal waived	23-10-12	AN
BioPharma Credit PLC Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
BioPharma Credit hails "attractive pipeline" and backs dividend target	23-09-27	AN
BioPharma Credit PLC Provides Dividend Guidance for the Full Year Ending December 31, 2023	23-09-27	CI

Chart BioPharma Credit PLC

Duration

Period

More charts

Company Profile

BioPharma Credit PLC is a United Kingdom-based closed-ended investment company. The principal activity of the Company is to invest in interest-bearing debt assets with a contractual right to future cash flows derived from royalties or sales of approved life sciences products. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve its investment objective predominantly through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt and credit linked notes. Its diversified portfolio is primarily secured by cash flows derived from sales of approved life sciences products. The Company holds a majority of its investments through its financing subsidiary, BPCR Limited Partnership. Its investment manager is Pharmakon Advisors L.P.

Sector

Closed End Funds

Calendar

2024-06-12 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.878

Average target price

Consensus

Sector Closed End Funds

	1st Jan change	Capi.
BIOPHARMA CREDIT PLC	+4.52%	1.08B
ARES CAPITAL CORPORATION	+3.74%	12.61B
PERSHING SQUARE HOLDINGS, LTD.	+5.50%	9.01B
FS KKR CAPITAL CORP.	-3.20%	5.41B
SPROTT PHYSICAL URANIUM TRUST FUND	+2.44%	5.25B
PIMCO DYNAMIC INCOME FUND	+5.63%	5.19B
SPROTT PHYSICAL SILVER TRUST	+14.36%	4.48B
SPROTT PHYSICAL GOLD AND SILVER TRUST	+16.67%	4.44B
MACQUARIE KOREA INFRASTRUCTURE FUND	+1.53%	4B
3I INFRASTRUCTURE PLC	+1.56%	3.75B

Closed End Funds